Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Apremilast and Methotrexate monotherapy on Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Next Previous
Trial Profile

Study of Apremilast and Methotrexate monotherapy on Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Disease-modifying antirheumatics; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine; Tofacitinib
  • Indications Psoriatic arthritis; Spondylarthritis
  • Focus Therapeutic Use

Most Recent Events

  • 15 Apr 2021 Results comparing patient characteristics and disease burden between men and women with axial spondyloarthritis, published in The Journal of Rheumatology
  • 15 Nov 2020 Results (n=150) of exploratory analysis evaluating whether apremilast monotherapy is an effective treatment option for oligoarticular PsA, published in The Journal of Rheumatology
  • 06 Jun 2020 Results (N=119), assessing trends in characteristics of patients starting apremilast from 2014-2019 and compare characteristics of treatment naive patients, presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top